Abstract
The threat of a highly pathogenic avian influenza (HPAI) H5N1 virus causing the next pandemic remains a major concern. In this study, we evaluated the immunogenicity and efficacy of an inactivated whole-virus H5N1 pre-pandemic vaccine (MG1109) formulated by Green Cross Co., Ltd containing the hemagglutinin (HA) and neuraminidase (NA) genes of the clade 1 A/Vietnam/1194/04 virus in the backbone of A/Puerto Rico/8/34 (RgVietNam/04xPR8/34). Administration of the MG1109 vaccine (2-doses) in mice and ferrets elicited high HI and SN titers in a dose-dependent manner against the homologous (RgVietNam/04xPR8/34) and various heterologous H5N1 strains, (RgKor/W149/06xPR8/34, RgCambodia/04xPR8/34, RgGuangxi/05xPR8/34), including a heterosubtypic H5N2 (A/Aquatic bird/orea/W81/05) virus. However, efficient cross-reactivity was not observed against heterosubtypic H9N2 (A/Ck/Korea/H0802/08) and H1N1 (PR/8/34) viruses. Mice immunized with 1.9 μg HA/dose of MG1109 were completely protected from lethal challenge with heterologous wild-type HPAI H5N1 A/EM/Korea/W149/06 (clade 2.2) and mouse-adapted H5N2 viruses. Furthermore, ferrets administered at least 3.8 μg HA/dose efficiently suppressed virus growth in the upper respiratory tract and lungs. Vaccinated mice and ferrets also demonstrated attenuation of clinical disease signs and limited virus spread to other organs. Thus, this vaccine provided immunogenic responses in mouse and ferret models even against challenge with heterologous HPAI H5N1 and H5N2 viruses. Since the specific strain of HPAI H5N1 virus that would potentially cause the next outbreak is unknown, pre-pandemic vaccine preparation that could provide cross-protection against various H5 strains could be a useful approach in the selection of promising candidate vaccines in the future.
Article PDF
Similar content being viewed by others
References
Baras, B., Stittelaar, K.J., Simon, J.H., Thoolen, R.J., Mossman, S.P., Pistoor, F.H., van Amerongen, G., Wettendorff, M.A., Hanon, E., and Osterhaus, A.D. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3, e1401.
Benne, C.A., Harmsen, M., De Jong, J.C., and Kraaijeveld, C.A. 1994. Neutralization enzyme immunoassay for influenza virus. J. Clin. Microbiol. 32, 987–990.
Bodewes, R., Kreijtz, J.H., van Amerongen, G., Geelhoed-Mieras, M.M., Verburgh, R.J., Heldens, J.G., Bedwell, J., van den Brand, J.M., Kuiken, T., van Baalen, C.A., and et al. 2010. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J. Virol. 84, 7943–7952.
Chin, P.S., Hoffmann, E., Webby, R., Webster, R.G., Guan, Y., Peiris, M., and Shortridge, K.F. 2002. Molecular evolution of H6 influenza viruses from poultry in Southeastern China: prevalence of H6N1 influenza viruses possessing seven A/Hong Kong/156/97 (H5N1)-like genes in poultry. J. Virol. 76, 507–516.
Choi, Y.K., Nguyen, T.D., Ozaki, H., Webby, R.J., Puthavathana, P., Buranathal, C., Chaisingh, A., Auewarakul, P., Hanh, N.T., Ma, S.K., and et al. 2005. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J. Virol. 79, 10821–10825.
Clements, C.J. and Griffiths, E. 2002. The global impact of vaccines containing aluminium adjuvants. Vaccine 20, S24–S33.
De, B.P., Joannis, T.M., Lombin, L.H., Shittu, I., Beato, M.S., Rebonato, V., Cattoli, G., and Capua, I. 2007. Field and laboratory findings of the first incursion of the Asian H5N1 highly pathogenic avian influenza virus in Africa. Avian Pathol. 36, 115–117.
Gherardi, R.K., Coquet, M., Cherin, P., Belec, L., Moretto, P., Dreyfus, P.A., Pellissier, J.F., Chariot, P., and Authier, F.J. 2001. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124, 1821–1831.
Govorkova, E.A., Webby, R.J., Humberd, J., Seiler, J.P., and Webster, R.G. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194, 159–167.
Hampson, A.W. 2006. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis. 194, 143–145.
Harada, Y., Ninomiya-Mori, A., Takahashi, Y., Shirakura, M., Kishida, N., Kageyama, T., Tada, Y., Tashiro, M., and Odagiri, T. 2011. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 29, 8330–8337.
Hoffmann, E., Krauss, S., Perez, D., Webby, R., and Webster, R.G. 2002. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20, 3165–3170.
Horimoto, T., Takada, A., Fujii, K., Goto, H., Hatta, M., Watanabe, S., Iwatsuki-Horimoto, K., Ito, M., Tagawa-Sakai, Y., Yamada, S., and et al. 2006. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24, 3669–3676.
Isoda, N., Sakoda, Y., Kishida, N., Soda, K., Sakabe, S., Sakamoto, R., Imamura, T., Sakaguchi, M., Sasaki, T., Kokumai, N., and et al. 2008. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia. Arch. Virol. 153, 1685–1692.
Lee, Y.J., Choi, Y.K., Kim, Y.J., Song, M.S., Jeong, O.M., Lee, E.K., Jeon, W.J., Jeong, W., Joh, S.J., Choi, K.S., and et al. 2008. Highly pathogenic avian influenza virus (H5N1) in domestic poultry and relationship with migratory birds, South Korea. Emerg. Infect. Dis. 14, 487–490.
Leroux-Roels, I., Bernhard, R., Gerard, P., Drame, M., Hanon, E., and Leroux-Roels, G. 2008. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3, e1665.
Lindblad, E.B. 2004. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497–505.
Lipatov, A.S., Hoffmann, E., Salomon, R., Yen, H.L., and Webster, R.G. 2006. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J. Infect. Dis. 194, 1040–1043.
Lu, X., Tumpey, T.M., Morken, T., Zaki, S.R., Cox, N.J., and Katz, J.M. 1999. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J. Virol. 73, 5903–5911.
Mahmood, K., Bright, R.A., Mytle, N., Carter, D.M., Crevar, C.J., Achenbach, J.E., Heaton, P.M., Tumpey, T.M., and Ross, T.M. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26, 5393–5399.
Miyaki, C., Quintilio, W., Miyaji, E.N., Botosso, V.F., Kubrusly, F.S., Santos, F.L., Iourtov, D., Higashi, H.G., and Raw, I. 2010. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 28, 2505–2509.
Murakami, S., Iwasa, A., Iwatsuki-Horimoto, K., Ito, M., Kiso, M., Kida, H., Takada, A., Nidom, C.A., Mai, l.Q., Yamada, S., and et al. 2008. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26, 6398–6404.
Nidom, C.A., Takano, R., Yamada, S., Sakai-Tagawa, Y., Daulay, S., Aswadi, D., Suzuki, T., Suzuki, Y., Shinya, K., Iwatsuki-Horimoto, K., and et al. 2010. Influenza A (H5N1) viruses from pigs, Indonesia. Emerg. Infect. Dis. 16, 1515–1523.
Palmer, D.F., Dowdle, W.R., Coleman, M.T., and Schild, G.C. 1975. Advanced laboratory techniques for influenza diagnosis. Immun. Ser. 6, 25–45.
Park, K.J., Kwon, H.I., Song, M.S., Pascua, P.N., Baek, Y.H., Lee, J.H., Jang, H.L., Lim, J.Y., Mo, I.P., Moon, H.J., and et al. 2011. Rapid evolution of low-pathogenic H9N2 avian influenza viruses following poultry vaccination programmes. J. Gen. Virol. 92, 36–50.
Reed, L.J. and Muench, H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493–497.
Sabirovic, M., Raw, L., Hall, S., Lock, F., and Coulson, N. 2006. International disease monitoring, October to December 2005. Vet. Rec. 158, 426–428.
Salzberg, S.L., Kingsford, C., Cattoli, G., Spiro, D.J., Janies, D.A., Aly, M.M., Brown, I.H., Couacy-Hymann, E., De Mia, G.M., Dung, d.H., and et al. 2007. Genome analysis linking recent European and African influenza (H5N1) viruses. Emerg. Infect. Dis. 13, 713–718.
Schickli, J.H., Flandorfer, A., Nakaya, T., Martinez-Sobrido, L., Garcia-Sastre, A., and Palese, P. 2001. Plasmid-only rescue of influenza A virus vaccine candidates. Philos. Trans. R. Soc. Lond B Biol. Sci. 356, 1965–1973.
Shi, W.F., Gibbs, M.J., Zhang, Y.Z., Zhang, Z., Zhao, X.M., Jin, X., Zhu, C.D., Yang, M.F., Yang, N.N., Cui, Y.J., and et al. 2008. Genetic analysis of four porcine avian influenza viruses isolated from Shandong, China. Arch. Virol. 153, 211–217.
Shortridge, K.F. 1999. Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: abridged chronology and virus isolation. Vaccine 17, S26–S29.
Sims, L.D., Domenech, J., Benigno, C., Kahn, S., Kamata, A., Lubroth, J., Martin, V., and Roeder, P. 2005. Origin and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet. Rec. 157, 159–164.
Smith, G.J., Fan, X.H., Wang, J., Li, K.S., Qin, K., Zhang, J.X., Vijaykrishna, D., Cheung, C.L., Huang, K., Rayner, J.M., and et al. 2006. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. USA 103, 16936–16941.
Song, M.S., Oh, T.K., Pascua, P.N., Moon, H.J., Lee, J.H., Baek, Y.H., Woo, K.J., Yoon, Y., Sung, M.H., Poo, H., and et al. 2009a. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Vaccine 27, 3145–3152.
Song, M.S., Pascua, P.N., Lee, J.H., Baek, Y.H., Lee, O.J., Kim, C.J., Kim, H., Webby, R.J., Webster, R.G., and Choi, Y.K. 2009b. The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. J. Virol. 83, 12325–12335.
Subbarao, K., Chen, H., Swayne, D., Mingay, L., Fodor, E., Brownlee, G., Xu, X., Lu, X., Katz, J., Cox, N., and et al. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192–200.
Subbarao, K. and Luke, C. 2007. H5N1 viruses and vaccines. PLoS Pathog. 3, e40.
Suguitan, A.L.Jr., McAuliffe, J., Mills, K.L., Jin, H., Duke, G., Lu, B., Luke, C.J., Murphy, B., Swayne, D.E., Kemble, G., and et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3, e360.
Webster, R.G., Guan, Y., Peiris, M., Walker, D., Krauss, S., Zhou, N.N., Govorkova, E.A., Ellis, T.M., Dyrting, K.C., Sit, T., and et al. 2002. Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J. Virol. 76, 118–126.
World Health Organization. 2008. H5N1 avian influenza: timeline of major events.
World Health Organization. 2011. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO.
Yamada, S., Suzuki, Y., Suzuki, T., Le, M.Q., Nidom, C.A., Sakai-Tagawa, Y., Muramoto, Y., Ito, M., Kiso, M., Horimoto, T., and et al. 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444, 378–382.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, MS., Moon, HJ., Kwon, Hi. et al. Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models. J Microbiol. 50, 478–488 (2012). https://doi.org/10.1007/s12275-012-1573-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-012-1573-z